Observational studyOrphanet journal of rare diseases2026
Real world outcomes of Fabry disease in Italian excellence centers: the ground study.
Observational study in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundA better understanding of Fabry Disease (FD) in terms of diagnostic journey, patient profile and use of available treatments remains topical. The Global buRden and treatment trajectOries in Italian patients with Fabry disease: a retrospective longitUdinal and cross-sectioNal study-GROUND was designed to provide a comprehensive overview of a real-world FD Italian cohort.
methodsThis was a retrospective, multicenter, longitudinal and cross-sectional study of adult FD patients of either sex with ≥ 3 years of follow-up. Severe/fatal events from birth to last visit was the composite primary outcome. Secondary outcomes were disease progression measured by FAbry STabilization indEX (FASTEX); disease activity assessed by clinically significant events/FD related symptoms; time from first manifestation to diagnosis; treatment trajectories.
results199 patients, 73 males and 126 females, 169 classic and 30 late-onset phenotypes, were enrolled at 8 Italian centers. Mean time from first FD symptom to diagnosis was 5.03 years (range 0.00-43.90), with a median of 0.64 years (range 0-19.29) from diagnosis to start of FD specific treatment. Initial manifestations were chronic pain (18.1%), angiokeratomas (13.1%), acroparesthesia and abdominal pain (12.5%), or left ventricular hypertrophy (LVH) (8.5%). 143 missense/nonsense GLA variants were identified. 82% patients were actively treated with one of the FD specific therapies, 24% had switched ≥ 1 treatment, while 5% had definitively stopped treatment. The primary outcome was experienced by 31.7% of patients for a total of 85 severe/fatal events, mainly in the treated cohort: 20.6% had a cardiac event, 11.1% a cerebral event 7.5% patients experienced a renal event, while fatal events occurred in 7 patients (3.5%). 88.9% reported ≥ 1 clinically significant event, with detection/worsening of LVH being the most common (41.2%). Estimated Glomerular Filtration rate (eGFR) slopes in last 1-3 years of follow-up were - 2.07 ml/min/m
conclusionsEven though FD patients were promptly treated, severe clinical events occurred in about 30%, mainly classic males, highlighting the need for sensitive tools assessing outcomes and novel therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.